BridgeBio Enters Collaboration with UCSF to Accelerate the Development of Therapies for Genetic Diseases

Rare Daily Staff

BridgeBio Pharma has entered into a partnership with the University of California, San Francisco to drive the advancement of academic innovations in genetically-driven diseases into potential therapeutics for patients.

“UCSF is a global leader in scientific innovation and genetic disease research, and we are proud to establish a formal, long-term relationship with the university as we work to help patients as quickly and safely as possible,” said BridgeBio CEO and founder Neil Kumar.
 
Following a six-month pilot collaboration, the new agreement establishes a three-year alliance between UCSF and BridgeBio with the goal of identifying early translational research to accelerate into clinical development and potential commercialization. The partnership is designed to foster close collaboration between the two entities that builds on their respective strengths, and will initially be structured to enable Sponsored Research Agreements for certain labs working between UCSF Innovation Ventures and BridgeBio. These collaborations may lead to the creation of BridgeBio affiliate companies to support clinical development.

“The BridgeBio team is developing close relationships with our investigators at UCSF with the mission of bringing potential therapies into the clinic quickly, where they have the opportunity to help patients in need,” said Barry Selick, UCSF vice chancellor for business development, innovation, and partnerships and director of the Office of Innovation Ventures.

Photo: BridgeBio CEO and founder Neil Kumar.